Scienture Holdings shares fall 42.23% intraday amid $41.5M net loss, impairment charges, and commercialization costs.

Scienture Holdings plummeted 42.23% intraday following the release of its FY2025 earnings and 10-K filing, which revealed a $41.5 million net loss, a $2.70 loss per share, and a $26.3 million non-cash impairment charge. Despite a 216% year-over-year revenue increase to $432,000 driven by the ARBLI™ launch, the company's heavy operating losses and significant cash burn highlighted challenges in scaling its specialty pharmaceutical business. The negative earnings report, combined with ongoing Nasdaq compliance concerns and regulatory delays, triggered a sharp selloff as investors reacted to deteriorating profitability and financial strain.